Prevention and treatment of synucleinopathic and amyloidogenic disease
AssigneesNeotope Biosciences Limited, The Regents of the University of California
InventorsDale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
Life of this patent
Estimating the term…
Abstract
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
Claims4
A method of treating, reducing the risk of, lessening the severity of, or delaying the outset of a disease characterized by Lewy bodies or alpha-synuclein aggregation in the brain, the method comprising administering to a patient having or at risk of the disease an effective regime of an antibody that specifically binds to human alpha-synuclein (SEQ ID:1), wherein the antibody is 1H7 (ATCC accession number PTA-8220) or a humanized or chimeric form thereof.
Dependencies are inferred from the claim text.